Evidence map›Paper›PMID 34129887›Full record

ArticleJournal of hepatology2021

Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis.

Mohamed Bou Saleh, Alexandre Louvet, Line Carolle Ntandja-Wandji, Emmanuel Boleslawski, Viviane Gnemmi, Guillaume Lassailly, Stéphanie Truant, François Maggiotto, Massih Ningarhari, Florent Artru and 10 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 80 citations in OpenAlex.

  1. Article
  2. Review
  3. Lipid Droplet Dynamics in Alcoholic Steatohepatitis.The American journal of pathology · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. MST1/2 DKO abates salvianolic acid B's therapeutic effect on CClNaunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  10. Article
  11. Dopamine receptor D1-mediated suppression of liver fibrosisWorld journal of gastroenterology · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 3 countries.

Mohamed Bou SalehUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Alexandre LouvetUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Line Carolle Ntandja-WandjiUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Emmanuel BoleslawskiUniv. Lille, Inserm, CHU Lille, U1189 - ONCO-THAI - Image Assisted Laser Therapy for Oncology, F-59000 Lille, France.
Viviane GnemmiCHU Lille, Service d'Anatomopathologie, F-59000 Lille, France.
Guillaume LassaillyUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Stéphanie TruantCHU Lille, Service de Chirurgie Digestive et Transplantations, F-59000 Lille, France.
François MaggiottoUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Massih NingarhariUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Florent ArtruUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Emilie AngloUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Pau Sancho-BruInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain.
Anne CorluINSERM, Univ Rennes, INRAE, Institut NuMeCan (Nutrition, Metabolisms and Cancer), F-35043, Rennes, France.
Josepmaria ArgemiDivision of Gastroenterology, Hepatology and Nutrition. Pittsburgh Liver Research Center. University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.
Julie Dubois-ChevalierUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.
Sébastien DharancyUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France.
Jérôme EeckhouteUniv. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011-EGID, F-59000 Lille, France.
Ramon BatallerDivision of Gastroenterology, Hepatology and Nutrition. Pittsburgh Liver Research Center. University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA, USA.
Philippe MathurinUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France. Electronic address: philippe.mathurin@chru-lille.fr.
Laurent DubuquoyUniv. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France. Electronic address: laurent.dubuquoy@inserm.fr.
Inserm · FRCentre Hospitalier Universitaire de Lille · FRUniversity of Pittsburgh Medical Center · USCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ES

Funding

Pittsburgh Liver Research CenterP30DK120531 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shuchang Silvia Liu · 2019 to 2026
$10.9M
Molecular Subtypes for Targeted Therapies in Alcoholic HepatitisU01AA021908 · NIAAA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BATALLER, RAMON · 2013 to 2017
$6.0M
NIAAA NIH HHS U01 AA021908NIDDK NIH HHS P30 DK120531
6 · The paper itself

Abstract

BACKGROUND &

aimsAlcoholic hepatitis (AH) is a life-threatening disease with limited therapeutic options, as the molecular mechanisms leading to death are not well understood. This study evaluates the Hippo/Yes-associated protein (YAP) pathway which has been shown to play a role in liver regeneration.

methodThe Hippo/YAP pathway was dissected in explants of patients transplanted for AH or alcohol-related cirrhosis and in control livers, using RNA-seq, real-time PCR, western blot, immunohistochemistry and transcriptome analysis after laser microdissection. We transfected primary human hepatocytes with constitutively active YAP (YAPS127A) and treated HepaRG cells and primary hepatocytes isolated from AH livers with a YAP inhibitor. We also used mouse models of ethanol exposure (Lieber de Carli) and liver regeneration (carbon tetrachloride) after hepatocyte transduction of YAPS127A.

resultsIn AH samples, RNA-seq analysis and immunohistochemistry of total liver and microdissected hepatocytes revealed marked downregulation of the Hippo pathway, demonstrated by lower levels of active MST1 kinase and abnormal activation of YAP in hepatocytes. Overactivation of YAP in hepatocytes in vitro and in vivo led to biliary differentiation and loss of key biological functions such as regeneration capacity. Conversely, a YAP inhibitor restored the mature hepatocyte phenotype in abnormal hepatocytes taken from patients with AH. In ethanol-fed mice, YAP activation using YAPS127A resulted in a loss of hepatocyte differentiation. Hepatocyte proliferation was hampered by YAPS127A after carbon tetrachloride intoxication.

conclusionAberrant activation of YAP plays an important role in hepatocyte transdifferentiation in AH, through a loss of hepatocyte identity and impaired regeneration. Thus, targeting YAP is a promising strategy for the treatment of patients with AH. LAY SUMMARY: Alcoholic hepatitis is characterized by inflammation and a life-threatening alteration of liver regeneration, although the mechanisms behind this have not been identified. Herein, we show that liver samples from patients with alcoholic hepatitis are characterized by profound deregulation of the Hippo/YAP pathway with uncontrolled activation of YAP in hepatocytes. We used human cell and mouse models to show that inhibition of YAP reverts this hepatocyte defect and could be a novel therapeutic strategy for alcoholic hepatitis.

Indexed as

AnimalsDisease Models, AnimalFemaleFranceHepatitis, AlcoholicHepatocytesMiceYAP-Signaling ProteinsYAP-Signaling Proteinsalcoholic hepatitishepatocyteHippo/YAPregenerationtransdifferentiation

Identifiers

PMID34129887
PMCPMC11868489
OpenAlexW3168356415

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.